Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Registry sponsor category
Industry
- Other names
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Company name
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Organisation type
- Industry
- Registry sponsor category
- Industry
- Publicly traded (proxy)
- No
- Listing at source
- Listed
Related records
Trials (60)
- 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
- 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
- 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
- A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
- A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
- A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
- A Phase 3 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
- A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
- A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
- A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma
- A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma
- A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
- A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients
- A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
- A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
- A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
- A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
- A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
- A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.